WebEnabling precise in vivo engineering of cells with payloads necessary to benefit patients across multiple disease categories. Capstan is combining the power of in vivo cell therapy with the precision of genetic medicines to develop new treatment options for patients across oncology, fibrosis, inflammation-related diseases, and monogenic blood disorders. Our … WebNov 15, 2024 · Courtesy of Getty Images. Three months after selling an immuno-oncology platform developed by Good Therapeutics to Roche, founder John Mulligan launched Bonum Therapeutics Tuesday with $93 million in Series A financing.. Bonum was created to develop new drugs based on the proprietary platform of allosterically regulated, …
Durham cancer therapy firm G1 to expand sales force, ends co-promotion ...
WebMar 20, 2024 · Founder & Chief Executive Officer at Bonum Therapeutics . Dr. John Mulligan is a scientist and executive with 30 years of experience in research management, drug discovery, company formation and business d evelopment. Prior to founding Good Therapeutics he was the founder and CEO of Glycostasis, where he invented a glucose … business 410
Roche takes another punt on IL-2 in cancer with Good takeover
WebSep 8, 2024 · Roche Pharma Partnering global head James Sabry said: “We are excited to bring Good’s innovative PD-1-regulated IL-2 programme into our existing oncology … WebJul 9, 2024 · 07-09-2024 Print. Privately-held Seattle, USA-based drug developer Good Therapeutics today revealed that it has entered into a definitive agreement to be acquired by Swiss pharma giant Roche (ROG: SIX). With this acquisition, Roche will gain rights to Good Therapeutics’ innovative, conditionally active, PD-1-regulated interleukin (IL)-2 ... WebDec 30, 2024 · (Good Therapeutics Photo) The news: Seattle startup Good Therapeutics has raised $8 million to advance its therapeutic proteins designed to operate only where … business 41202